Quote:
Originally Posted by 'Hamas' Jenkins
Not much more than you do, probably. Upon briefly reading an article, it seems that it may not have great activity in human respiratory cells, which you'd obviously want when fighting a virus attacking alveoli. That's something that a lot of providers don't consider--drugs often have vastly different penetration depending upon what organ you are speaking of.
There is a powerful antibiotic that can be used for MRSA called Daptomycin, but you can't use it in lung infections because it is inactivated by pulmonary surfactant. Cefpodoxime is a good antibiotic, but it doesn't achieve good concentration in the urine, so it's not good against UTIs, etc.
There is a Chinese study where it performed better than Kaletra with interferon alpha, but is that due to an interaction between Kaletra and interferon or is favipravir truly better? It was an open-label study, both Kaletra and interferon can be hepatotoxic (although favipravir is also hepatotoxic). It's just too hard to tell.
Watching people's reactions to this reminds me of reading about early therapies thought to work against HIV. Patients (including Rock Hudson) traveled from all over the world to go to Paris to receive a drug called HPA-23, doctors actually conducted trials with a drug that was not legal to import in the US called trichosanthin (which was an extract from a Chinese root). In the end, one compound developed in the 60s was effective (AZT was a failed cancer drug developed at NIH), but it was years before truly effective therapies emerged.
|
They had some success with it in China which you know if they’re complimenting the Japanese it must have worked
Read one study that it had really good success with mild and moderate cases which would make some sense in regards to the respiratory issue